[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652721":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":42,"locations":48,"responsibleParty":69,"collaborators":28,"id":71,"slug":72,"hasResults":73,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":73,"sex":79,"minAge":80,"maxAge":28,"enrollmentInfo":81,"targetDuration":28,"studyType":84,"phases":85,"briefSummary":87,"conditions":88,"keywords":96,"overallStatus":51,"whyStopped":28,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":115},{"fullName":5,"class":6},"Revolution Medicines, Inc.","INDUSTRY",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Arm A: zoldonrasib + pembrolizumab + chemotherapy doublet","EXPERIMENTAL","study drug in combination with pembrolizumab and platinum-based chemotherapy doublet",[13,14,15],"Drug: zoldonrasib","Drug: pembrolizumab","Drug: pemetrexed + cisplatin \u002Fcarboplatin",{"label":17,"type":18,"description":19,"interventionNames":20},"Arm B: placebo + pembrolizumab + chemotherapy doublet","PLACEBO_COMPARATOR","placebo in combination with pembrolizumab and platinum-based chemotherapy doublet",[21,14,15],"Drug: Placebo",[23,29,32,36],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","zoldonrasib","oral tablets",[9],null,{"type":24,"name":30,"description":26,"armGroupLabels":31,"otherNames":28},"Placebo",[17],{"type":24,"name":33,"description":34,"armGroupLabels":35,"otherNames":28},"pembrolizumab","IV infusion or Subcutaneous injection",[9,17],{"type":24,"name":37,"description":38,"armGroupLabels":39,"otherNames":40},"pemetrexed + cisplatin \u002Fcarboplatin","IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin",[9,17],[41],"Platinum-based chemotherapy doublet",[43],{"name":44,"role":45,"phone":46,"phoneExt":28,"email":47},"Revolution Medicines Study Director","CONTACT","1-844-2-REVMED","medinfo@revmed.com",[49],{"facility":50,"status":51,"city":52,"state":53,"zip":54,"country":55,"countryCode":56,"cosmosGeoPoint":57,"geoPoint":62,"contacts":63},"Florida Clinical Trials Group, LLC","RECRUITING","Plantation","Florida","33322","United States","US",{"type":58,"coordinates":59},"Point",[60,61],-80.23184,26.13421,{"lat":61,"lon":60},[64],{"name":65,"role":45,"phone":66,"phoneExt":67,"email":68},"Sandra Perez","772-297-3057","Ext 102","perezs@floridactg.com",{"type":70,"investigatorFullName":28,"investigatorTitle":28,"investigatorAffiliation":28,"oldNameTitle":28,"oldOrganization":28},"SPONSOR","100652721","phase-3-study-of-pembrolizumab--pemetrexed--platinum-chemotherapy-with-or-without-zoldonrasib-as-first-line-treatment-in-metastatic-non-squamous-ras-g12d-mutated-nsclc-100652721",false,"NCT07777822","Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC","A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer (RASolve 308)","RASolve 308","Inclusion Criteria:\n\n* At least 18 years old and has provided informed consent.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Histologically or cytologically confirmed, previously untreated metastatic non-squamous NSCLC.\n* Known PD-L1 status\n* Documented RAS G12D mutation status.\n* Measurable disease per RECIST v1.1.\n* Adequate organ function (bone marrow, liver, kidney, coagulation, thyroid).\n* Able to take oral medications.\n\nExclusion Criteria:\n\n* Prior treatment with systemic anticancer therapy in metastatic setting for NSCLC.\n* Prior systemic therapy with any RAS-directed therapy.\n* Untreated (symptomatic or asymptomatic) central nervous system metastatic disease.\n* Any conditions that may affect the ability to take or absorb study drug.\n* Major surgery on or within 28 days prior to randomization.\n* Patient is unable or unwilling to comply with protocol-required study visits or procedures.\n* Additional inclusion and exclusion criteria may apply","ALL","18 Years",{"count":82,"type":83},430,"ESTIMATED","INTERVENTIONAL",[86],"PHASE3","The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.",[89,90,91,92,93,94,95],"NSCLC","Non-small Cell Lung Cancer","Non-Small Cell Lung Cancer NSCLC","Non-Squamous Non Small Cell Lung Cancer","Lung Cancer (NSCLC)","Metastatic NSCLC - Non-Small Cell Lung Cancer","Metastatic Non-Squamous Non-Small Cell Lung Cancer",[89,97,92,95,98,99,100,101,102,103,104,105],"Non-Small Cell Lung Cancer","RAS","KRAS","NRAS","HRAS","RAS Mutation","Lung Cancer","G12D","RAS G12D","2026-08-17",{"date":108,"type":109},"2026-08-20","ACTUAL",{"date":111,"type":109},"2026-08-14",{"date":113,"type":83},"2031-02",{"name":5,"class":6},1]